Treatment of generalized infantile myofibromatosis with sorafenib and imatinib: A case report

Behzad Bidadi, Andrea Watson, Brenda Weigel, Andre Oliveira, Justin Kirkham, Carola Arndt

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Infantile myofibromatosis (IM) is characterized by solitary musculoskeletal nodules presenting during infancy but can manifest as multiple lesions with visceral involvement. Multicentric IM with visceral involvement carries a high risk of mortality and there is no consensus on treatment. We present a case of a patient with multicentric IM and pulmonary involvement who progressed on several chemotherapeutic regimens and subsequently had a complete response to sorafenib and later imatinib. This report describes the novel use of sorafenib and imatinib to treat generalized IM and the role of continued tyrosine kinase inhibitor therapy to maintain remission.

Original languageEnglish (US)
Article numbere28288
JournalPediatric Blood and Cancer
Issue number6
StatePublished - Jun 1 2020

Bibliographical note

Funding Information:
This work was supported by the Mayo Clinic Children's Research Center.

Publisher Copyright:
© 2020 Wiley Periodicals, Inc.


  • imatinib
  • infantile myofibromatosis
  • soft tissue tumor
  • sorafenib
  • targeted therapy

PubMed: MeSH publication types

  • Case Reports
  • Journal Article
  • Research Support, Non-U.S. Gov't


Dive into the research topics of 'Treatment of generalized infantile myofibromatosis with sorafenib and imatinib: A case report'. Together they form a unique fingerprint.

Cite this